Literature DB >> 12044649

The administration of complement component C9 augments post-ischemic cerebral infarction volume in neonatal rats.

Mitchell D Imm1, Pamela W Feldhoff, Richard C Feldhoff, Herbert A Lassiter.   

Abstract

To determine whether ischemic cerebral infarction is mediated in part by complement component C9, C9-deficient neonatal rats were subjected to unilateral cerebral ischemia. Brains were harvested 24 h later, stained with 2,3,5-triphenyl tetrazolium chloride, and cerebral infarct volumes were quantified by computer-based planimetry. Compared with buffer, prophylactic intraperitoneal (i.p.) administration of the complement inhibitors soluble complement receptor type 1 (sCR1), a molecular hybrid of sCR1 and the selectin inhibitor sialyl Lewis x (sCR1-sLex), or cobra venom factor did not affect the cerebral infarct volume. In contrast, i.p. human C9 (75 microg/g body weight) significantly increased the volume of infarct located 6 through 10 mm posterior to the frontal pole. Therefore, in the post-ischemic brain, C9 was neurotoxic and augmented the focal cerebral infarct volume.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12044649     DOI: 10.1016/s0304-3940(02)00271-9

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  13 in total

Review 1.  Neuroprotection in stroke by complement inhibition and immunoglobulin therapy.

Authors:  T V Arumugam; T M Woodruff; J D Lathia; P K Selvaraj; M P Mattson; S M Taylor
Journal:  Neuroscience       Date:  2008-07-12       Impact factor: 3.590

2.  The alternative complement pathway propagates inflammation and injury in murine ischemic stroke.

Authors:  Andrew Elvington; Carl Atkinson; Hong Zhu; Jin Yu; Kazue Takahashi; Gregory L Stahl; Mark S Kindy; Stephen Tomlinson
Journal:  J Immunol       Date:  2012-10-01       Impact factor: 5.422

3.  Complement component c1q mediates mitochondria-driven oxidative stress in neonatal hypoxic-ischemic brain injury.

Authors:  Vadim S Ten; Jun Yao; Veniamin Ratner; Sergey Sosunov; Deborah A Fraser; Marina Botto; Baalasubramanian Sivasankar; B Paul Morgan; Samuel Silverstein; Raymond Stark; Richard Polin; Susan J Vannucci; David Pinsky; Anatoly A Starkov
Journal:  J Neurosci       Date:  2010-02-10       Impact factor: 6.167

4.  Delayed post-injury administration of C5a improves regeneration and functional recovery after spinal cord injury in mice.

Authors:  Q Guo; J Cheng; J Zhang; B Su; C Bian; S Lin; C Zhong
Journal:  Clin Exp Immunol       Date:  2013-11       Impact factor: 4.330

Review 5.  Injury site-specific targeting of complement inhibitors for treating stroke.

Authors:  Ali Alawieh; Stephen Tomlinson
Journal:  Immunol Rev       Date:  2016-11       Impact factor: 12.988

6.  Relation of platelet C4d with all-cause mortality and ischemic stroke in patients with systemic lupus erythematosus.

Authors:  Amy H Kao; Christine A McBurney; Abdus Sattar; Apinya Lertratanakul; Nicole L Wilson; Sarah Rutman; Barbara Paul; Jeannine S Navratil; Andrea Scioscia; Joseph M Ahearn; Susan Manzi
Journal:  Transl Stroke Res       Date:  2013-10-27       Impact factor: 6.829

7.  Membrane attack complex inhibitor CD59a protects against focal cerebral ischemia in mice.

Authors:  Denise Harhausen; Uldus Khojasteh; Philip F Stahel; B Paul Morgan; Wilfried Nietfeld; Ulrich Dirnagl; George Trendelenburg
Journal:  J Neuroinflammation       Date:  2010-03-04       Impact factor: 8.322

8.  Systemic complement activation following human acute ischaemic stroke.

Authors:  E D Pedersen; U Waje-Andreassen; C A Vedeler; G Aamodt; T E Mollnes
Journal:  Clin Exp Immunol       Date:  2004-07       Impact factor: 4.330

Review 9.  Aberrant Complement System Activation in Neurological Disorders.

Authors:  Karolina Ziabska; Malgorzata Ziemka-Nalecz; Paulina Pawelec; Joanna Sypecka; Teresa Zalewska
Journal:  Int J Mol Sci       Date:  2021-04-28       Impact factor: 5.923

Review 10.  Complement in the Homeostatic and Ischemic Brain.

Authors:  Ali Alawieh; Andrew Elvington; Stephen Tomlinson
Journal:  Front Immunol       Date:  2015-08-12       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.